It is to be noted that KRAS mutation is not the deterministic carcinogenic factor for CRC but acts in combination with other carcinogenic and clinicopathologic factors such as patient sex, age, consistent molecular subtypes, and tumor staging. However, other scientists believe that the mutation rate of the KRAS gene is not related to such clinicopathologic factors as gender, age, degree of differentiation, tumor location, and type of specimen [20]. Here, KRAS is linked to neoplasm.